Press Releases

CRH Q1 2024 Results May 10, 2024 02:00AM

DUBLIN--(BUSINESS WIRE)-- CRH plc (NYSE: CRH) (LSE: CRH):

 

Key Highlights 

 

 

Summary Financials

Q1 2024

Change

 

 

Total revenues

$6.5bn

+2%

 

 

Net income

$114m

n/m1

 

 

Net income margin

1.7%

+220bps

 

 

Adjusted EBITDA*

$445m

+15%

 

 

Adjusted EBITDA margin*

... (continue reading...)

Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease May 10, 2024 02:00AM

• Agreement Adds to Shionogi’s Growing Pipeline in Rare Disease
• MZE001 has the Potential to be the First Oral Therapy for Pompe Disease

OSAKA, Japan & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) and Maze Therapeutics, Inc. (Head Office: South San Francisco, California, USA; Chief Executive Officer: Jason Coloma, Ph.D.; hereafter... (continue reading...)

Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines May 10, 2024 02:00AM

• Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards
• Provides Novavax with cash and an equity investment totalling approximately $1.2 billion (upfront payment of $500 million and up to $700 million in additional development, regulatory and launch milestones), plus tiered royalties
• Novavax is entitled to additional launch and sales milestone opportunities of up... (continue reading...)

Decisions of the Annual General Meeting of shareholders of Arco Vara AS May 10, 2024 02:00AM

The annual general meeting of shareholders of Arco Vara AS held on 9 May 2024 adopted the following decisions:

To approve the annual report of Arco Vara AS for 2023.

To allocate the net profit for the year ended on 31 December 2023 in the amount of 3,550 thousand EUR to retained earnings.

To pay dividends to the shareholders 0.06 euros per share. The dividend will be paid out in 4 instalments as follows:

• 0.02 euros per share will be paid to the shareholders... (continue reading...)

Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines May 10, 2024 02:00AM

  Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines

• Agreement provides patients with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards
• Accelerates potential for development of a novel flu-COVID-19 combination product based on authorized vaccines with demonstrated efficacy and tolerability,... (continue reading...)